[{"symbol": "VRTX", "publishedDate": "2019-06-29 16:35:00", "title": "Three Growth Stocks to Buy and Hold for the Next 50 Years", "image": "https://cdn.snapi.dev/images/v1/2/v/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5298912fa-hand-placing-a-coin-on-a-stack-of-coinsjpgw700opresize.jpg", "site": "The Motley Fool", "text": "This alcohol maker, drug company, and utility should generate steady growth for their investors in the decades ahead.", "url": "https://www.fool.com/investing/2019/06/29/3-growth-stocks-to-buy-and-hold-for-the-next-50-ye.aspx?source=iedfolrf0000001"}, {"symbol": "VRTX", "publishedDate": "2019-06-27 09:30:15", "title": "10 Names That Are Screaming Stocks to Buy", "image": "https://cdn.snapi.dev/images/v1/e/s/esy27-2.jpg", "site": "InvestorPlace", "text": "Even in these unstable times, there are still gems to be found. These 10 stocks share a \"strong buy\" analyst consensus rating from the Street and compelling growth drivers.", "url": "https://investorplace.com/2019/06/10-stocks-that-are-screaming-buys-right-now/"}, {"symbol": "VRTX", "publishedDate": "2019-06-26 13:31:10", "title": "Vertex Pharmaceuticals Is A Good Long-Term Investment", "image": "https://cdn.snapi.dev/images/v1/s/t/biotech37.jpg", "site": "Seeking Alpha", "text": "Vertex has a high P/E compared to other large-cap biotechs.", "url": "https://seekingalpha.com/article/4272240-vertex-pharmaceuticals-good-long-term-investment?source=feed_tag_long_ideas"}, {"symbol": "VRTX", "publishedDate": "2019-06-25 11:02:00", "title": "The 10 Biggest Biotech Stocks", "image": "https://cdn.snapi.dev/images/v1/u/r-2/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5295332fbiotech-conceptjpgw700opresize.jpg", "site": "The Motley Fool", "text": "Here's how these biotech stocks became the biggest on the market -- and how their future prospects look.", "url": "https://www.fool.com/investing/2019/06/25/the-10-biggest-biotech-stocks.aspx?source=iedfolrf0000001"}, {"symbol": "VRTX", "publishedDate": "2019-06-24 10:05:00", "title": "Vertex's (VRTX) Symdeko Gets FDA Nod for Use in Children", "image": "https://cdn.snapi.dev/images/v1/t/o/biotech4.jpg", "site": "Zacks Investment Research", "text": "Vertex's (VRTX) Symdeko gets FDA approval to treat underlying cause of cystic fibrosis in children aged 6-11 years with certain mutations in the CFTR gene.", "url": "https://www.zacks.com/stock/news/433546/vertexs-vrtx-symdeko-gets-fda-nod-for-use-in-children"}, {"symbol": "VRTX", "publishedDate": "2019-06-22 08:00:00", "title": "3 Stocks That Could Double Your Money: GH, TTD & VRTX", "image": "https://cdn.snapi.dev/images/v1/p/9/sto2934.jpg", "site": "The Motley Fool", "text": "Great businesses plus great growth opportunities could add up to 100% or more returns for these stocks.", "url": "https://www.fool.com/investing/2019/06/22/3-stocks-that-could-double-your-money.aspx?source=iedfolrf0000001"}, {"symbol": "VRTX", "publishedDate": "2019-06-20 19:15:02", "title": "Vertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $9.8 million of Shares", "image": "https://cdn.snapi.dev/images/v1/r/q/biotech22.jpg", "site": "GuruFocus", "text": "CEO & President of Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Jeffrey M Leiden sold 56,030 shares of VRTX on 06/18/2019 at an average price of $175.39 a share.", "url": "https://www.gurufocus.com/news/897700/vertex-pharmaceuticals-inc-vrtx-ceo--president-jeffrey-m-leiden-sold-98-million-of-shares"}, {"symbol": "VRTX", "publishedDate": "2019-06-20 08:31:47", "title": "Check Out These 5 Fast-Growing Stocks to Buy Today", "image": "https://cdn.snapi.dev/images/v1/e/t/etf23-34.jpg", "site": "InvestorPlace", "text": "Growth is on a different track now, and here are some great ideas for stocks to buy to ride the momentum.", "url": "https://investorplace.com/2019/06/7-fast-growing-stocks-to-buy-today/"}, {"symbol": "VRTX", "publishedDate": "2019-06-17 16:31:29", "title": "Vertex Makes Strong Push Into Crispr Tech With 2 Deals At Once", "image": "https://cdn.snapi.dev/images/v1/a/z/biotech13.jpg", "site": "Seeking Alpha", "text": "Vertex is really committed into advancing CRISPR technology to develop treatments for DMD and other neurological disorders, proven by the expanded agreement with CRISPR Therapeutics and acquisition of Exonics.", "url": "https://seekingalpha.com/article/4270691-vertex-makes-strong-push-crispr-tech-2-deals?source=feed_tag_long_ideas"}, {"symbol": "VRTX", "publishedDate": "2019-06-16 17:00:00", "title": "3 Cheap Drug Stocks You Can Buy Right Now", "image": "https://cdn.snapi.dev/images/v1/l/h/jnj-2.jpg", "site": "The Motley Fool", "text": "Not all stocks are expensive. These drug stocks look like bargains.", "url": "https://www.fool.com/investing/2019/06/16/3-cheap-drug-stocks-you-can-buy-right-now.aspx?source=iedfolrf0000001"}, {"symbol": "VRTX", "publishedDate": "2019-06-14 14:59:58", "title": "7 Top-Rated Biotech Stocks to Invest In Today", "image": "https://cdn.snapi.dev/images/v1/b/i/biotechmsn.jpg", "site": "InvestorPlace", "text": "Despite the trade dispute with China, these biotech stocks each earn top marks in Portfolio Grader for fundamentals, earnings and momentum.", "url": "https://investorplace.com/2019/06/7-healthy-biotech-stocks-to-invest-in/"}, {"symbol": "VRTX", "publishedDate": "2019-06-14 07:22:36", "title": "3 Big Stock Charts for Friday: Symantec, Vertex Pharmaceuticals and Nektar Therapeutics", "image": "https://cdn.snapi.dev/images/v1/e/t/etf29-37.jpg", "site": "InvestorPlace", "text": "Stock charts of VRTX, NKTR and SYMC are going to end the trading week knocking on the door of major moves.", "url": "https://investorplace.com/2019/06/3-big-stock-charts-for-friday-symantec-vertex-pharmaceuticals-and-nektar-therapeutics/"}, {"symbol": "VRTX", "publishedDate": "2019-06-12 08:15:00", "title": "5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit", "image": "https://cdn.snapi.dev/images/v1/u/r-2/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5284572ffemale-scientist-with-pipette-in-labjpgw700opresize.jpg", "site": "The Motley Fool", "text": "New blockbusters could be on the way for five drugmakers.", "url": "https://www.fool.com/investing/2019/06/12/5-most-valuable-pipeline-drugs-in-development-and.aspx?source=iedfolrf0000001"}, {"symbol": "VRTX", "publishedDate": "2019-06-11 14:39:27", "title": "Crispr: Vertex Doubled Down On The Reigning Champion CRISPR/Cas9", "image": "https://cdn.snapi.dev/images/v1/k/u/biotech19.jpg", "site": "Seeking Alpha", "text": "Due to its stellar CRISPR/Cas9 platform, CRISPR Therapeutics is able to expand its collaborative relationship with the pharmaceutical elite, Vertex.", "url": "https://seekingalpha.com/article/4269689-crispr-vertex-doubled-reigning-champion-crispr-cas9?source=feed_tag_long_ideas"}, {"symbol": "VRTX", "publishedDate": "2019-06-11 09:30:15", "title": "CELG or VRTX: Which Is the Better Value Stock Right Now?", "image": "https://cdn.snapi.dev/images/v1/n/u/biotech12.jpg", "site": "Zacks Investment Research", "text": "CELG vs. VRTX: Which Stock Is the Better Value Option?", "url": "https://www.zacks.com/stock/news/427825/celg-or-vrtx-which-is-the-better-value-stock-right-now"}, {"symbol": "VRTX", "publishedDate": "2019-06-09 12:15:00", "title": "3 Healthcare Stocks I'd Buy Right Now", "image": "https://cdn.snapi.dev/images/v1/s/e/se23-6.jpg", "site": "The Motley Fool", "text": "Illumina, Teladoc Health, and Vertex Pharmaceuticals enjoy strong competitive advantages and great growth opportunities.", "url": "https://www.fool.com/investing/2019/06/09/3-healthcare-stocks-id-buy-right-now.aspx?source=iedfolrf0000001"}, {"symbol": "VRTX", "publishedDate": "2019-06-09 07:27:00", "title": "Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy?", "image": "https://cdn.snapi.dev/images/v1/b/i/biotech38-8.jpg", "site": "The Motley Fool", "text": "Vertex Pharmaceuticals recently doubled down on its gene editing collaboration with CRISPR Therapeutics, but it's miles behind an arguably simpler solution.", "url": "https://www.fool.com/investing/2019/06/09/gene-therapy-vs-gene-editing-which-is-better-for-t.aspx?source=iedfolrf0000001"}, {"symbol": "VRTX", "publishedDate": "2019-06-07 12:04:38", "title": "Why This Vertex Buyout Could Signal A Buying Spree In Gene Editing", "image": "https://cdn.snapi.dev/images/v1/s/l/biotech9.jpg", "site": "Investors Business Daily", "text": "Vertex Pharmaceuticals is betting on gene-editing treatments with the acquisition of private biotech company Exonics Therapeutics and a deeper collaboration with Crispr Therapeutics.\nThe post Why This Vertex Buyout Could Signal A Buying Spree In Gene Editing appeared first on Investor's Business Daily.", "url": "https://www.investors.com/news/technology/biotech-companies-buying-spree-gene-editing-treatments/"}, {"symbol": "VRTX", "publishedDate": "2019-06-07 09:54:05", "title": "Vertex Signs Gene Editing Deals With Crispr, Exonics Worth Up To $2 Billion", "image": "https://cdn.snapi.dev/images/v1/d/n/dna-3656587-1920-0.jpg", "site": "Benzinga", "text": "Gene editing is an emerging field, and\u00a0Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)\u00a0 is plunging headlong into it with two deals announced Thursday after the market close.", "url": "https://www.benzinga.com/general/biotech/19/06/13881293/vertex-signs-gene-editing-deals-with-crispr-exonics-worth-up-to-2-billion"}, {"symbol": "VRTX", "publishedDate": "2019-06-07 09:24:00", "title": "Vertex Expands Collaboration With CRISPR, Acquires Exonics", "image": "https://cdn.snapi.dev/images/v1/b/9/biotech8.jpg", "site": "Zacks Investment Research", "text": "Vertex (VRTX) is expanding its gene editing pipeline into new disease areas by expanding collaboration with CRISPR Therapeutics and acquiring Exonics.", "url": "https://www.zacks.com/stock/news/426146/vertex-expands-collaboration-with-crispr-acquires-exonics"}, {"symbol": "VRTX", "publishedDate": "2019-06-05 18:16:40", "title": "Vertex's Latest Data May Lead To Expanded Cystic Fibrosis Market", "image": "https://cdn.snapi.dev/images/v1/h/w/biotech2.jpg", "site": "Seeking Alpha", "text": "Vertex picks VX-445 as triplet therapy to move on with for regulatory approval in the U.S. and European Union to treat patients with cystic fibrosis.", "url": "https://seekingalpha.com/article/4268568-vertexs-latest-data-may-lead-expanded-cystic-fibrosis-market?source=feed_tag_long_ideas"}, {"symbol": "VRTX", "publishedDate": "2019-06-04 14:12:00", "title": "5 Biotech Stocks to Buy Right Now", "image": "https://cdn.snapi.dev/images/v1/o/u/biotech13.jpg", "site": "Zacks Investment Research", "text": "here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank #2 (Buy) or better.", "url": "https://www.zacks.com/stock/news/424754/5-biotech-stocks-to-buy-right-now"}, {"symbol": "VRTX", "publishedDate": "2019-05-31 08:25:00", "title": "Vertex Selects Triple Combo Regimen for Regulatory Submission", "image": "https://cdn.snapi.dev/images/v1/w/8/vertex-2.jpg", "site": "Zacks Investment Research", "text": "Vertex (VRTX) choses VX-445 triple combination regimen for global regulatory submissions to seek approval for the regimen as a treatment for cystic fibrosis based on 24-week phase III study data.", "url": "https://www.zacks.com/stock/news/422781/vertex-selects-triple-combo-regimen-for-regulatory-submission"}, {"symbol": "VRTX", "publishedDate": "2019-05-30 11:59:39", "title": "This Biotech Just Inched Closer To Treating 90% Of Cystic Fibrosis Patients", "image": "https://cdn.snapi.dev/images/v1/v/e/ver-2.jpg", "site": "Investors Business Daily", "text": "Vertex Pharmaceuticals said Thursday it selected the three-drug cystic fibrosis treatment it plans to submit to regulators in the U.S. and Europe.", "url": "https://feedproxy.google.com/~r/InternetTechnologyRss/~3/0iVR6n3mmkY/"}, {"symbol": "VRTX", "publishedDate": "2019-05-30 09:31:56", "title": "Why Is Vertex (VRTX) Down 3.5% Since Last Earnings Report?", "image": "https://cdn.snapi.dev/images/v1/p/2/biotech34.jpg", "site": "Zacks Investment Research", "text": "Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?", "url": "https://www.zacks.com/stock/news/422166/why-is-vertex-vrtx-down-35-since-last-earnings-report"}, {"symbol": "VRTX", "publishedDate": "2019-05-29 13:39:22", "title": "3 Large-Cap Stocks With Superior Performances", "image": "https://cdn.snapi.dev/images/v1/e/t/etf26-22.jpg", "site": "GuruFocus", "text": "Several large-cap stocks have had positive performances over the past month, year to date, the last 12 months and past three years.", "url": "https://www.gurufocus.com/news/886199/3-largecap-stocks-with-superior-performances-"}, {"symbol": "VRTX", "publishedDate": "2019-05-28 20:15:03", "title": "Vertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $19.9 million of Shares", "image": "https://cdn.snapi.dev/images/v1/j/1/biotech7.jpg", "site": "GuruFocus", "text": "CEO & President of Vertex Pharmaceuticals Inc. Jeffrey M Leiden sold 113,432 shares of VRTX on 05/24/2019 at an average price of $175.1 a share.", "url": "https://www.gurufocus.com/news/885963/vertex-pharmaceuticals-inc-vrtx-ceo--president-jeffrey-m-leiden-sold-199-million-of-shares"}, {"symbol": "VRTX", "publishedDate": "2019-05-26 09:00:00", "title": "3 Big Biotech Stocks That Warren Buffett Might Like", "image": "https://cdn.snapi.dev/images/v1/b/u/bu8s3.jpg", "site": "The Motley Fool", "text": "There's at least one thing about these biotechs that the Oracle of Omaha should find especially appealing.", "url": "https://www.fool.com/investing/2019/05/26/3-big-biotech-stocks-warren-buffett-might-like.aspx?source=iedfolrf0000001"}, {"symbol": "VRTX", "publishedDate": "2019-05-13 09:27:50", "title": "5 Growthy Biotech Stocks to Buy Despite the Scrutiny", "image": "https://cdn.snapi.dev/images/v1/0/9/092314-0028-nvsholdwith1.jpg", "site": "InvestorPlace", "text": "Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?", "url": "https://feedproxy.google.com/~r/InvestorPlace/~3/yuNrJUL6pnI/"}, {"symbol": "VRTX", "publishedDate": "2019-05-12 09:00:00", "title": "My Top Stock to Buy in May", "image": "https://cdn.snapi.dev/images/v1/x/q/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5245142fscientist-holding-a-test-tubejpgw700opresize.jpg", "site": "The Motley Fool", "text": "This biotech checks off the two most important criteria that the greatest stocks have.", "url": "https://www.fool.com/investing/2019/05/12/heres-my-top-stock-to-buy-in-may.aspx?source=iedfolrf0000001"}, {"symbol": "VRTX", "publishedDate": "2019-05-08 09:30:18", "title": "CELG vs. VRTX: Which Stock Should Value Investors Buy Now?", "image": "https://cdn.snapi.dev/images/v1/h/b/biotech13.jpg", "site": "Zacks Investment Research", "text": "CELG vs. VRTX: Which Stock Is the Better Value Option?", "url": "https://www.zacks.com/stock/news/410995/celg-vs-vrtx-which-stock-should-value-investors-buy-now"}, {"symbol": "VRTX", "publishedDate": "2019-05-02 15:47:00", "title": "Vertex Pharmaceuticals Looks to Jump From 18,000 Patients to 68,000", "image": "https://cdn.snapi.dev/images/v1/t/f/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5230852fcystic-fibrosis.jpg", "site": "The Motley Fool", "text": "The biotech's cystic fibrosis treatment potential is far from over.", "url": "https://www.fool.com/investing/2019/05/02/vertex-pharmaceuticals-looks-to-jump-from-18000-pa.aspx?source=iedfolrf0000001"}, {"symbol": "VRTX", "publishedDate": "2019-05-02 08:15:00", "title": "5 Things You Need to Know From Vertex Pharmaceuticals' Q1 Earnings Update", "image": "https://cdn.snapi.dev/images/v1/p/i/vert2.jpg", "site": "The Motley Fool", "text": "Vertex started off 2019 on a positive note. But even better days are almost certainly on the way.", "url": "https://www.fool.com/investing/2019/05/02/5-things-you-need-to-know-from-vertex-pharmaceutic.aspx?source=iedfolrf0000001"}, {"symbol": "VRTX", "publishedDate": "2019-05-01 11:46:00", "title": "Vertex (VRTX) Q1 Earnings and Revenues Surpass Estimates", "image": "https://cdn.snapi.dev/images/v1/t/a/biotech28.jpg", "site": "Zacks Investment Research", "text": "Vertex (VRTX) beats on both earnings and sales in Q1 with demand for its newest CF drug, Symdeko, rising high.", "url": "https://www.zacks.com/stock/news/406789/vertex-vrtx-q1-earnings-and-revenues-surpass-estimates"}, {"symbol": "VRTX", "publishedDate": "2019-04-30 23:53:08", "title": "Vertex Pharmaceuticals Incorporated (VRTX) CEO Jeff Leiden on Q1 2019 Results - Earnings Call Transcript", "image": "https://cdn.snapi.dev/images/v1/f/b/transcript41.jpg", "site": "Seeking Alpha", "text": "Vertex Pharmaceuticals Incorporated (VRTX) CEO Jeff Leiden on Q1 2019 Results - Earnings Call Transcript", "url": "https://seekingalpha.com/article/4258360-vertex-pharmaceuticals-incorporated-vrtx-ceo-jeff-leiden-q1-2019-results-earnings-call?source=feed_sector_transcripts"}, {"symbol": "VRTX", "publishedDate": "2019-04-30 16:24:02", "title": "Cystic Fibrosis-Focused Biotech Easily Tops First-Quarter Estimates", "image": "https://cdn.snapi.dev/images/v1/v/e/vertex-3.jpg", "site": "Investors Business Daily", "text": "Vertex earnings of $1.14 a share on $857 million in sales beat the forecasts of Wall Street analysts when it reported late Tuesday. But Vertex stock remained flat in after-hours action.", "url": "https://feedproxy.google.com/~r/InternetTechnologyRss/~3/gMUd3ZPHvus/"}, {"symbol": "VRTX", "publishedDate": "2019-04-28 17:00:00", "title": "Top Biotech Stocks to Buy Right Now", "image": "https://cdn.snapi.dev/images/v1/u/r-2/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5213462fscientists-working-in-lab.jpg", "site": "The Motley Fool", "text": "The future looks incredibly bright for these three businesses.", "url": "https://www.fool.com/investing/2019/04/28/3-top-biotech-stocks-to-buy-right-now.aspx?source=iedfolrf0000001"}, {"symbol": "VRTX", "publishedDate": "2019-04-24 16:32:00", "title": "What's in Store for Vertex (VRTX) This Earnings Season?", "image": "https://cdn.snapi.dev/images/v1/7/0/biotech22.jpg", "site": "Zacks Investment Research", "text": "On Vertex's (VRTX) first-quarter earnings call, investor focus will be on its latest CF drug Symdeko's sales figure as well as the update on its CF triple-pill regimes.", "url": "https://www.zacks.com/stock/news/398972/whats-in-store-for-vertex-vrtx-this-earnings-season"}, {"symbol": "VRTX", "publishedDate": "2019-04-24 15:01:00", "title": "Everything You Need to Know About Investing in Healthcare", "image": "https://cdn.snapi.dev/images/v1/u/r-2/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5199432fhealthcare-icons-on-wood-blocks.jpg", "site": "The Motley Fool", "text": "The global demand for healthcare products and services will keep growing significantly. Here's your complete guide to finding the best healthcare stocks and ETFs.", "url": "https://www.fool.com/investing/2019/04/24/everything-you-need-to-know-about-investing-in.aspx?source=iedfolrf0000001"}, {"symbol": "VRTX", "publishedDate": "2019-04-22 14:33:57", "title": "Two investors make the case for why now is the time to invest in health care stocks", "image": "https://cdn.snapi.dev/images/v1/m/q-3/two-investors-make-the-case-for-why-now-is-the-time-to-invest-in-health-care-stocks.jpg", "site": "CNBC Television", "text": "Michael Yee, Jefferies Biotech analyst, and Les Funtleyder, E-Squared Capital Management, join 'The Exchange' to discuss the health care sector and why investors are taking their bets off the stocks.", "url": "https://www.youtube.com/watch?v=C95nFfG5VRA"}, {"symbol": "VRTX", "publishedDate": "2019-04-19 14:12:00", "title": "5 Top Pharmaceutical Stocks to Buy in 2019", "image": "https://cdn.snapi.dev/images/v1/u/r-2/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5178452fscientist-holding-a-test-tube.jpg", "site": "The Motley Fool", "text": "Some are really big, while others are relatively small. But all these pharmaceutical stocks look like promising picks for 2019.", "url": "https://www.fool.com/investing/2019/04/19/5-top-pharmaceutical-stocks-to-buy-in-2019.aspx?source=iedfolrf0000001"}, {"symbol": "VRTX", "publishedDate": "2019-04-19 12:19:00", "title": "5 Top Biotech Stocks to Buy in 2019", "image": "https://cdn.snapi.dev/images/v1/u/r-2/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5122902ftest-tubes-with-arrow.jpg", "site": "The Motley Fool", "text": "Looking for potential winning biotech stocks? These five check off all the boxes for investors.", "url": "https://www.fool.com/investing/2019/04/19/5-top-biotech-stocks-to-buy-in-2019.aspx?source=iedfolrf0000001"}, {"symbol": "VRTX", "publishedDate": "2019-04-19 11:02:00", "title": "5 Top Healthcare Stocks to Buy in 2019", "image": "https://cdn.snapi.dev/images/v1/h/c/hc6-2.jpg", "site": "The Motley Fool", "text": "Healthcare is hot, and these top healthcare stocks could be among the hottest of them all this year.", "url": "https://www.fool.com/investing/2019/04/19/5-top-healthcare-stocks-to-buy-in-2019.aspx?source=iedfolrf0000001"}, {"symbol": "VRTX", "publishedDate": "2019-04-17 15:50:00", "title": "Pharmas That Own Their Markets", "image": "https://cdn.snapi.dev/images/v1/v/e/vert2-2.jpg", "site": "Forbes", "text": "To take some of the complexity of investing in pharma stocks, look at the companies that dominate their markets.", "url": "https://www.forbes.com/sites/kenberman/2019/04/17/pharmas-that-own-their-markets/"}, {"symbol": "VRTX", "publishedDate": "2019-04-17 07:14:00", "title": "Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag", "image": "https://cdn.snapi.dev/images/v1/b/i/biotech5-9.jpg", "site": "Zacks Investment Research", "text": "FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for a second indication - transfusion-dependent beta thalassemia.", "url": "https://www.zacks.com/stock/news/382503/vertex-crisprs-gene-editing-drug-gets-fdas-fast-track-tag"}, {"symbol": "VRTX", "publishedDate": "2019-04-09 11:07:48", "title": "Why Vertex Pharmaceuticals Could Conceivably Succeed Too Well", "image": "https://cdn.snapi.dev/images/v1/v/e/ver.jpg", "site": "The Motley Fool", "text": "The sky is the limit for this biotech leader.", "url": "https://www.fool.com/investing/2019/04/09/why-vertex-pharmaceuticals.aspx?source=iedfolrf0000001"}]